

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

R.D. Neirinckx

Patent Art Unit: 1653

Serial No.: 09/584,978

Examiner: Moezie

Filed: 2 June 2000

For:

TREATMENT OF PSORIASIS THROUGH:

DOWN-REGULATION OF THE

EGF-RECEPTOR WITH TOPICALLY-

APPLIED EGF

## RESPONSE TO RESTRICTION REQUIREMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

In the Communication mailed 28 August 2001, the Examiner identified three groups of claims:

I. Claims1–3, 7 and 8;

II. Claims 4–6; and

III. Claims 9 and 10.

CAMPEGEIVED NOV-1/5/2008)

OFFICE OF PETITIONS

RECEIVED

NOV 1 9 2002

**REMARKS** 

OFFICE OF PETITIONS

Applicant elects with traverse Group II, claims 4-6.

The invention relates to the treatment of psoriasis with at least EGF as the primary active agent. Thus, claims 1–3 and 7–10, which are directed to a formulation for treating psoriasis using EGF, would be covered in a search of claims 4–6. It is noted that the projected search of